John L. Flavin
Lead Independent DirectorMr. John L. Flavin, MBA, Ph.D. was Director of TRACT Therapeutics, Inc. He serves as Founder, Board Member and Chief Executive Officer of Portal Innovations LLC.since February 2020. He is co-founder of Pyxis Oncology, Inc. and has been its Director since May 2019 and Serves as Lead Independent Director since September 04, 2026 and was its Chair of the Board since October 2021 until September 04, 2026. He has been Executive Chairman at ClostraBio, Inc. board member at Syntax Bio, Inc.He serves as the Managing Director of Flavin Ventures, LLC. He serves as the Chief Executive Officer of Cell Habitats, Inc. He served as President of Advanced Life Sciences Holdings, Inc. since August 2004 and has been its Chief Financial Officer since April 18, 2008. Mr. Flavin served as Principal Accounting Officer and Secretary of Advanced Life Sciences Holdings, Inc. He served as President of Flavin Ventures, LLC since 2004. He has experience in the life sciences field focused on finance and operations. Over his career, Mr. Flavin successfully built a series of companies and the requisite business and scientific teams focused on discovery and development of novel therapeutics. He joined Flavin Ventures in June 2002 as an Executive Vice President and Chief Financial Officer. He served as the Chief Operating Officer and Executive Vice President of MediChem Life Sciences, Inc. since May 2000 and served as its Secretary. Since 1996, Mr. Flavin served as Vice President of Operations at MediChem Life Sciences. He was a Co-Founder and Chief Executive Officer of MediChem Life Sciences, Inc. At MediChem, Mr. Flavin was responsible for developing and managing the business and scientific operations and was the Chief Executive Officer of its protein engineering and proteomics subsidiaries, Emerald BioStructures, ThermoGen and AXAS. In addition, he led each of Advanced Life Sciences' and MediChem's capital financings including 2 IPOs. Mr. Flavin also led the establishment of MediChem's IT / financial reporting functions and project management systems. He serves as an Executive Chairman and Director at ALTATHERA Pharmaceuticals, LLC. He served as Chairman of the Board at Advanced Life Sciences, Inc. and has been its Director since 2003. He has been a Director of Flavin Ventures, LLC since 2003. Mr. Flavin serves on the Lewis University President’s Council of Regents. He serves as a Board Member at the Illinois Science and Technology Coalition. He serves as an Executive Director of the Chicago Innovation Exchange at the University of Chicago. He served as an Executive Director of Chicago Innovation Mentors, Northwestern University, University of Illinois, Argonne National Laboratory and Propel focused on commercializing complex technology innovation and entrepreneurship. He is also the Associate Vice President of Entrepreneurship and Innovation at the University of Chicago. He served as a Director of MediChem Life Sciences, Inc. since June 1999. Mr. Flavin guest lectures regularly at the University of Chicago Booth Graduate School of Business in the area of biotechnology entrepreneurship. He was awarded the Marquette University College of Business Young Alumnus of the Year and is a KPMG Illinois High Tech Award winner. Mr. Flavin holds an M.B.A. from Lewis University and a B.S. in Business Administration from Marquette University.Between September 2013 and April 2018, Mr. Flavin was the Head of the Polsky Center for Entrepreneurship and Innovation at the University of Chicago.
Positions
- Company NamePyxis Oncology, Inc.Stock CodePYXSPositionLead Independent DirectorColleagues
- TCThomas CivikCEO & Chairman
- JWJitendra WadhaneChief Accounting Officer, Senior VP of Finance, Corporate Controller & Principal Financial Officer
- BNBalu N. BalasubramanianInterim Chief Technology Officer
- DRDonna RegaladoHead of Human Resources
- CTCharles T. GombarSenior Vice President of Portfolio & Program Management
- DSDarren S. ClineIndependent Director
- MRMorris RosenbergChairperson of Technical Advisory Board
- COChristopher O’DonnellMember of Technical Advisory Board
